Investment
Features
FeesSafety
Academy
More
Pluang+

Preferred stocks backed by Bitcoin treasury firms fueled demand for 135,979 BTC in just over a year.

Market News
20 Oct 2026
Crypto Briefing
View Source
Bullish
Preferred stocks backed by Bitcoin treasury firms fueled demand for 135,979 BTC in just over a year.

Fidelity Digital Assets reports that perpetual preferred stocks issued by Bitcoin treasury companies have financed the purchase of 135,979 BTC since late 2024, representing over 0.5% of Bitcoin's total supply. These preferred stocks act like bonds with no maturity, allowing companies to raise capital from income-focused investors and buy more Bitcoin without issuing new common shares or traditional debt. The trend accelerated in 2026, with more than $7 billion raised between March and May, buying over 95,000 BTC in that period alone. This method taps into the large fixed-income market and offers yields potentially higher than traditional cash equivalents, creating a new demand catalyst for Bitcoin. However, risks remain as dividend obligations persist regardless of Bitcoin's price volatility, testing the model's sustainability in downturns.

Fidelity's report on preferred stocks financing Bitcoin purchases provides context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 21, 2026 03:41 WIB: out of 50 major cryptocurrencies, 45 rose and 4 fell today. Notable movers include AXS at Rp18.925 with a 5.20% increase and 100% sell order activity, SNX at Rp4.060 up 4.96% with 75% buy orders, and MANA at Rp1.569 rising 4.74% with 87% sell orders.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
57 minutes ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
1 hour ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
2 hours ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App